Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Fig. 2

Progression-free survival and overall survival. a The Kaplan-Meier curve for progression-free survival for all treated patients. The median progression-free survival was 15 months (95% CI, 11 to not estimable). b The Kaplan-Meier curve for overall survival for all treated patients. The median overall survival was not reached. The dotted lines represent 95% confidence intervals

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us